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Posttranslational arginylation is critical for embryogenesis, cardiovascular development, and angiogenesis, but its
molecular effects and the identity of proteins arginylated in vivo are largely unknown. Here we report a global analysis
of this modification on the protein level and identification of 43 proteins arginylated in vivo on highly specific sites.
Our data demonstrate that unlike previously believed, arginylation can occur on any N-terminally exposed residue
likely defined by a structural recognition motif on the protein surface, and that it preferentially affects a number of
physiological systems, including cytoskeleton and primary metabolic pathways. The results of our study suggest that
protein arginylation is a general mechanism for regulation of protein structure and function and outline the potential
role of protein arginylation in cell metabolism and embryonic development.
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Introduction
Protein arginylation is an enigmatic posttranslational
modiﬁcation mediated by arginyl-tRNA-protein transferase
(ATE1) that transfers arginine (Arg) from tRNA onto proteins
[1]. Until recently it had been believed that arginylation can
only occur on the exposed N-terminus of aspartic acid (Asp),
glutamic acid (Glu), or cysteine (Cys); however, a single case of
the addition of Arg onto the side chain of Glu has been
recently identiﬁed in vivo [2].
Despite the fact that arginylation was originally discovered
more than 40 y ago [3,4], its biological functions are still
poorly understood. ATE1 enzyme is highly conserved in
evolution. Eukaryotic species, from yeast to human, appear to
contain only one arginyltransferase gene and no other known
enzymes with a similar activity. ATE1 is nonessential in yeast,
but required for embryogenesis in mammals [5]. Mouse Ate1
knockout results in embryonic lethality and severe defects in
cardiovascular development and angiogenesis [5]. It has been
believed that the molecular function of arginylation is to
induce degradation of the target protein substrates by the
ubiquitin-dependent N-end rule pathway [6]. Indeed, arginy-
lation by ATE1 induces rapid degradation of experimentally
constructed test proteins in yeast [6], and the half-life of RGS
family proteins in mammals has been shown to decrease upon
arginylation [7]. Recently, however, it has been found that
arginylation regulates structure and intracellular assembly of
beta actin in motile cells without affecting its short-term
metabolic stability [8], suggesting that the function of
arginylation in vivo may be more complex.
The most direct way to understand the function of protein
arginylation is by identifying the in vivo substrates of ATE1;
however, such identiﬁcation is difﬁcult for the following
reasons. First, arginylation by ATE1 is believed to involve
Arg-tRNA that is also utilized during protein synthesis, and to
result in the formation of a normal peptide bond. As a result,
arginylated proteins are difﬁcult to distinguish in biochem-
ical tests or to label differentially from other intracellular
proteins. Second, arginylation is believed to occur only on the
N-terminally exposed residues other than methionine (Met) 1
found in all proteins immediately after translation initiation;
therefore, arginylation requires a preceding posttranslational
modiﬁcation either by proteolysis or by aminopeptidation—
modiﬁcations whose targets are themselves poorly charac-
terized. Finally, the situation is further complicated by the
cases where arginylation results in decreased metabolic
stability, making at least some arginylated proteins less
abundant in vivo. Thus, despite numerous evidence of
protein arginylation in vivo [9–14] and multiple attempts to
identify arginylated proteins, no systematic progress has been
made beyond identiﬁcation of several targets [7,15–19].
In this study we utilize the arginyltransferase knockout
(Ate1
 / ) mouse model [5] and use two-dimensional (2D) gel
fractionation, metabolic labeling by Arg, immunoafﬁnity
chromatography, and mass spectrometry (MS) to estimate
the entire complexity of arginylation, identify key proteins
arginylated in vivo, and gain insights into the biological
functions of arginylation as a posttranslational modiﬁcation.
Our analysis reveals that a vast number of proteins, on the
order of hundreds, are potentially arginylated in vivo. While
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PLoS BIOLOGYsome of these proteins are possibly metabolically destabilized
upon arginylation, a much larger number of proteins are not.
We ﬁnd that in addition to N-terminal Asp, Glu, and Cys,
proteins can be arginylated on other N-terminally exposed
amino acid residues, including one identiﬁed case of
arginylation on N-terminal Met. We further ﬁnd that proteins
arginylated in vivo fall into several distinct functional groups
with roles in cytoskeleton, transcriptional regulation, and
general metabolic pathways. These proteins are arginylated in
vivo on a limited number of sites predicted to affect their key
functional properties.
Our results suggest that protein arginylation plays a
general regulatory function in vivo by modulating the
structure of proteins and affecting their intracellular
functions.
Results
Protein Arginylation and Proteasome-Dependent Protein
Degradation
To estimate the complexity of effects of arginylation on the
protein level, we performed a comparison of all proteins up-
and down-regulated in response to arginylation in a
proteasome-degradation-dependent and -independent way.
To do that, we fractionated whole cell extracts from wild-type
immortalized ﬁbroblasts in culture (Figure 1A, panel 1), wild-
type ﬁbroblasts treated with proteasome inhibitor MG-132
(panel 2), and Ate1
 /  ﬁbroblasts derived from an Ate1
knockout mouse [5] (panel 3) by 2D gel electrophoresis, and
compared protein composition in the extracts (Figure 1).
Such analysis is estimated to resolve approximately 2,500
protein spots. To enable accurate comparison, cell extracts
were equalized by protein concentration, labeled with Cy2
(Figure 1A, panel 1), Cy3 (panel 2), and Cy5 (panel 3), ran on
the same gel, and visualized in three ﬂuorescence channels
(pictures in individual channels are shown in black and white
in the top set of images in Figure 1A, and their pairwise color
comparisons are shown in the bottom set of images).
A total of 1,030 different protein spots were found altered
between the three gels (Figure 1; Table S4). Of those, 297
spots were up- or down-regulated in response to the
treatment with proteasome inhibitor but showed no depend-
ence on the absence or presence of ATE1, being of similar
level in wild-type and Ate1
 /  extracts. The remaining 733
protein spots were altered in an Ate1-dependent way. These
spots were subjected to further analysis.
First, we estimated the number of spots whose arginylation
is likely to result in their degradation by the N-end rule
pathway. We reasoned that such spots would show increased
levels in Ate1
 /  compared to wild-type cells (indicating that
arginylation in wild-type cells results in their destabilization
and degradation), and that the same spots would be similarly
increased in wild-type cells treated with the proteasome
inhibitor (indicating that their degradation in wild-type cells
is proteasome-dependent). Surprisingly, out of the 733 spots
regulated by ATE1 only 83 showed such behavior.
The ‘‘N-end rule-independent’’ spots showed the following
patterns of regulation. A total of 313 spots were up-regulated
in wild-type cells compared to Ate1
 /  cells, but showed no
response to proteasome inhibitor treatment. A total of 110
spots were up-regulated in wild-type cells compared to Ate1
 / 
cells, while showing uncorrelated up- or down-regulation in
response to proteasome inhibitor, suggesting that regulation
of these proteins by arginylation and proteasome degrada-
tion are independent of each other. A total of 208 spots were
up-regulated in Ate1
 /  cells compared to wild-type cells, but
showed no dependence on proteasome inhibition. A total of
19 spots were up-regulated in Ate1
 /  cells compared to wild-
type cells, and showed various arginylation-independent
responses to proteasome inhibition. These results suggest
that while arginylation apparently regulates the levels of
many proteins, this regulation generally has no direct
correlation with their degradation by the proteasome, and
point to other functions of protein regulation by arginylation
or downstream effects of knocking out Ate1.
To identify proteins whose levels are regulated by either
arginylation or proteasome inhibition, we performed a
computerized comparison of protein spot composition on
individually run Coomassie-stained 2D gels of wild-type, MG-
132-treated, and Ate1
 /  cell extracts, excised spots clearly
visible by Coomassie staining that were up- or down-
regulated in response to Ate1 knockout or up-regulated in
response to proteasome inhibition, and performed their mass
spectrometric identiﬁcation. The names and accession
numbers of those proteins are listed in Tables S1 and S2.
We would like to point out that, given the complexity of the
samples, the presence of multiple proteins in some spots, and
the limited comparative abundance of some proteins, this list
does not cover, or deﬁnitively reﬂect, the entire complexity of
proteins regulated by arginylation. Limited abundance and
high complexity of the spots also precluded us from accurate
determination of the behavior of the speciﬁc identiﬁed
proteins in response to proteasome inhibition and Ate1
knockout.
Posttranslational Arg Incorporation into Proteins in
Cultured Cells
To identify proteins arginylated in vivo, we ﬁrst applied the
previously developed assays of posttranslational incorpora-
tion of radioactively labeled Arg into cells in culture in the
presence of protein synthesis inhibitors [9], and analyzed the
total homogenates from such cells by 2D gel autoradiography
(Figure 2). To distinguish between posttranslationally incor-
porated Arg and Arg incorporated into proteins during the
residual protein synthesis, we performed similar treatment of
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Author Summary
A common cellular mechanism for the regulation of proteins, once
they have been translated from mRNA, is the addition and removal
of chemical groups via enzymatic reactions. The posttranslational
addition of arginyl groups is critical for the embryonic development
and survival of an organism, but the molecular effects and the
identity of proteins arginylated in vivo are largely unknown. We
developed a technique to screen large numbers of proteins for this
modification and identified 43 proteins arginylated in vivo on highly
specific sites. Arginylation can occur on any exposed residue at the
N-terminus of a protein and appears to require a specific structural
recognition motif on the protein surface. It preferentially affects a
number of physiological systems, including cytoskeleton and
primary metabolic pathways and seems to be a general mechanism
for regulation of protein structure and function. Our data provide
insights into the previously unknown arginylation-dependent
mechanisms of the regulation of embryonic development.arginylation-deﬁcient cells derived from the Ate1
 /  mouse
(see above). We concluded that the spots showing increased
Arg incorporation in wild-type compared to Ate1
 /  cells
under these conditions represent proteins with posttransla-
tionally incorporated Arg.
Protein abundance in the majority of these spots was low,
which precluded accurate identiﬁcation of proteins in these
spots. However, we were able to excise 52 spots from
duplicate nonradioactive gels whose positions corresponded
to those circled in red in the wild-type gel shown in Figure 2.
Proteins in these spots were identiﬁed by MS (Table S3) and
represent potential arginylation targets in vivo. It should be
noted that the majority of these proteins were found at their
expected molecular weights, indicating that if they were
indeed arginylated, their arginylation was not accompanied
by degradatory proteolysis.
Since many of the excised spots contained more than one
protein, we could not tell deﬁnitively which of those proteins
were targets for arginylation. In addition, a large number of
the spots were not abundant enough for reliable MS
identiﬁcation. Therefore, we developed a deﬁnitive approach
to the mass target identiﬁcation in vivo.
Figure 1. 2D Gel Comparison of the Effects of Arginylation and Proteasome Degradation
(A) Top row: individual images of 10% 2D gels (pH range 3.5–10 increases left to right) of whole cell extracts from wild-type (þ/þ, WT) cells labeled with
Cy2 (1, left), WT cells treated with proteasome inhibitor labeled with Cy3 (2, middle), and arginylation-free Ate1
 /  cells labeled with Cy5 (3, right).
Bottom row: pairwise comparison of the gels shown on top in different fluorescence channels. Colors were altered to red and green to allow better
visual comparison.
(B) Quantification of the number of spots up- or down-regulated in response to each treatment. See also Table S4. Proteins identified in the most
abundant spots from Coomassie-stained gels obtained under similar conditions are listed in Tables S1 (reflecting the comparison between gels 1 and 3)
and S2 (reflecting the comparison between gels 1 and 2). See explanations in the text.
doi:10.1371/journal.pbio.0050258.g001
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Posttranslational Protein ArginylationIdentification of Proteins Arginylated In Vivo
To isolate and deﬁnitively identify proteins arginylated in
vivo, we raised two antibodies against N-terminally arginy-
lated proteins. As antigens we used peptides with N-terminal
Arg–Asp– and Arg–Glu– sequences (Figure 3, top), which are
the major known residues to be arginylated in vivo, and
incorporated these residues into a predictably highly immu-
nogenic epitope (identiﬁed in bold in the leftmost peptides in
Figure 3, top), followed by an amino acid stretch with
predicted low immunogenicity. Rabbit antiserum raised
against these peptides was ﬁrst afﬁnity puriﬁed on the
corresponding peptides, and then immunodepleted against
similar peptides without the N-terminal Arg–Asp– and Arg–
Glu–, followed by immunodepletion against ‘‘scrambled’’
peptides, i.e., peptides containing an epitope similar to that
of the original peptide but with the Arg–Asp– or Arg–Glu– in
the internal position. The resulting antibodies showed
extremely high speciﬁcity for the N-terminally arginylated
sequences without a strong speciﬁcity for the residue in the
second position (Figure 3, bottom). A similar attempt was
made with a peptide containing N-terminal Arg–Cys–
sequence; however, the resulting antibodies also recognized
the ‘‘scrambled’’ Arg–Cys– peptide, and thus were omitted
from our analysis.
We next covalently coupled the Arg–Asp– and Arg–Glu–
antibodies to Aminolink agarose (Pierce) and performed
immunoafﬁnity chromatography of whole cell extracts from
Figure 2. Posttranslational Incorporation of Arg into Proteins in Cultured Cells
Autoradiographs of wild-type (þ/þ) and Ate1
 /  ( / ) whole cell extracts treated with cycloheximide in medium containing
14C-Arg, fractionated on 2D
gels. Spots circled in red in the wild-type gel show increase in Arg incorporation above that in the Ate1
 /  cells, suggesting that Arg in these spots is
incorporated posttranslationally. Proteins identified in the most abundant of the up-regulated spots are listed in Table S3.
doi:10.1371/journal.pbio.0050258.g002
Figure 3. Generation of the Antibodies to N-Terminal Arg
Top: antibody generation strategy showing the sequences of the
peptides used for antibody production and immunodepletion to ensure
antibody specificity for Arg in the N-terminal position. Bottom: dot blot
of the affinity-purified antibodies to N-terminal Arg–Asp and Arg–Glu
sequences against the peptides listed on the top.
doi:10.1371/journal.pbio.0050258.g003
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Posttranslational Protein Arginylationseveral wild-type mouse tissues, including ﬁbroblasts, heart,
lung, liver, kidney, spleen, and brain; in addition, extracts
from whole embryos collected at embryonic day 12 were used
in the later parts of the analysis. Proteins bound to the
columns were eluted with glycine (pH 2.7), digested with a set
of proteases (varying combinations of trypsin, subtilisin,
elastase, and endopeptidase Lys-C) to achieve higher se-
quence coverage, and analyzed by MS. We found approx-
imately 300 proteins in the column eluates from two columns
with peptide antibodies, shown in Figure 3.
To identify which of these proteins were arginylated,
tandem MS (MS/MS) database searching was used to both
identify peptide amino acid sequences and to determine N-
terminal differential modiﬁcation with Arg [20,21]. Searches
yielded a large number of peptides within the initial list of
300 proteins identiﬁed that had an additional Arg (a mass of
156.1011). To eliminate potential false positives produced by
modiﬁcations other than arginylation that could result in a
similar mass change, we used stringent criteria for picking
out the putative arginylated peptides (see Materials and
Methods). We expect that by using these criteria a number of
true targets were sacriﬁced in favor of stringency, and thus
the list of arginylated proteins reported in this study is by no
means exhaustive.
The initial list of proteins contained 104 stringently picked
targets; however, several ambiguities were identiﬁed during
the analysis. First, peptides with N-terminally adjacent Arg in
the original protein sequence were discarded, since we had
no way to tell that these peptides were produced by
posttranslational arginylation and not proteolysis. Second,
peptides with N-terminally adjacent valine (Val)–glycine (Gly)
or Gly–Val sequence or an N-terminal Val, isoleucin (Ile),
leucine (Leu), or Asp residue were separated for further
veriﬁcation, since the masses of ValþGly (occurring naturally
in the peptide or produced by glycylation of Val due to the
presence of high concentration of Gly in the buffer),
carbamylated Ile or Leu (modiﬁed by urea used during
sample preparation), and acetylated Asp (occurring naturally
or during trichloroacetic acid precipitation of the samples)
are very close to the mass of Arg. To eliminate these
ambiguities, standard peptides of arginylated and non-
arginylated versions of these residues were produced and
analyzed by MS under similar conditions to compare to the
experimentally identiﬁed targets (See Dataset S2 for the
standard peptide spectra of the Val–Gly– versus Arg– case
and [8] for the acetylated versus arginylated spectra). Some of
the analysis was also repeated on the freshly prepared
antibody columns using high-salt elution conditions (3.5 M
MgCl2) instead of Gly, and further preparation of these
samples was done without urea.
Elimination of these ambiguities resulted in reduction of
the list of arginylated proteins to a ﬁnal list of 43 substrates,
shown in Table 1. MS/MS spectra of arginylated peptides for
these substrates were veriﬁed manually and are shown in
Figure 4 and Dataset S1 (except beta actin N-terminal
arginylated peptide, which was previously published [8]).
High mass accuracy of the precursor ions and the character-
istic pattern of b ion fragments in these spectra allowed
identiﬁcation of the arginylated positions within the proteins
shown in Table 1 with high conﬁdence.
Our analysis revealed several striking ﬁndings. First and
foremost, we found that arginylation can occur on various N-
terminally exposed residues, not only on Asp, Glu, or Cys, as
suggested before. We found evidence of almost every residue
arginylated on the N-terminus (Figure 4; Dataset S1),
including, remarkably, one case of arginylated N-terminal
Met (Figure 5 and Figure 19 of Dataset S1). Each protein was
found arginylated on a very limited number of sites, which in
some cases occurred repeatedly in different samples.
It has been previously suggested that N-terminal asparagine
(Asn) and glutamine (Gln) require deamidation in order to be
arginylated [22], and that arginylation of N-terminal Cys
requires a preceding oxidation [23]. In our analysis, however,
we found that Asn and Cys can be arginylated directly
without modiﬁcations (Figures 10, 14, 26, 35, and 44 of
Dataset S1).
As seen from Table 1, eight of the 43 identiﬁed proteins
were arginylated within several residues of the N-terminus,
including the previously identiﬁed actin [8] and a closely
related protein, ARP3, modiﬁed on a similar site. At the same
time the remaining 35 proteins were arginylated in the
middle of the molecule a signiﬁcant distance away from the
N-terminus. This suggests that such arginylation either occurs
on the side chains of the identiﬁed residues (in the cases
where such side chain modiﬁcations are chemically possible,
as shown in [2]) or requires a preceding cleavage of the
polypeptide chain to expose a free N-terminus of the
modiﬁed residue.
Analysis of the positions ﬂanking the arginylated residue
using the online WebLogo tool (http://weblogo.berkeley.edu/)
revealed that there is no apparent preference for particular
amino acids in the arginylation site itself and only a weak bias
for certain amino acid residues ﬂanking the arginylation site
(Figure S1). This apparent absence of the arginylation site
motif at the primary structure level suggests that arginylation
speciﬁcity for certain sites is deﬁned at the secondary or
higher structural level.
The identiﬁed arginylated proteins shown in Table 1 fall
into several distinct functional groups, with a very prominent
presence of cytoskeletal proteins and a notable representa-
tion of proteins involved in transcriptional regulation and
general metabolic pathways. There is no apparent bias toward
the overall abundance of arginylated proteins, suggesting that
arginylation is highly speciﬁc to certain functionally impor-
tant targets.
To further assess the possible role of arginylation in
modulating the activity of the proteins found on our list, we
selected a few targets from our list whose biological role is
well characterized and for which three-dimensional struc-
tures are available in a public database, including non-muscle
actin (PDB identiﬁer 1HLU), tubulin (1TUB), hemoglobin
(1DXT), GAPDH (1ZNQ), ARP3 (as part of ARP2/3 complex,
1K8K), 8-kDa dynein light chain (1PWK), and fragment of
calmodulin in complex with spectrin (2FOT). We then
‘‘mapped’’ the arginylation sites onto their structures. The
most complete molecular structures from this list available in
the database are shown in Figures 5 and 6. All mapped
arginylation sites (marked with red ‘‘R’’ for proteins shown in
Figures 5 and 6) are located on the surface of the assembled
molecule or the domain interface between the subunits. In
some cases (e.g., vimentin and talin, not shown), arginylated
sites are located at the interface between two domains and
cleavage at this interface might possibly result in the
production of functional protein fragments. Thus, it seems
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Posttranslational Protein Arginylationlikely that in all of the identiﬁed cases arginylation is involved
in modifying the surface properties and molecular inter-
actions of the protein targets without major structural or
functional perturbations.
Discussion
In this study we report a systematic characterization of
posstranslational protein arginylation and identiﬁcation of
43 proteins arginylated in vivo in different mouse tissues. Our
analysis shows that (1) arginylation can occur on almost any
N-terminally exposed residue without an apparent bias; (2)
arginylation occurs on a highly limited and conserved
number of sites in each protein located on the surface of
the assembled molecule, which suggests arginylation target
recognition by the secondary or higher order structure; and
(3) arginylation is functionally associated with proteins
involved in cytoskeleton and primary metabolic pathways.
It has been previously suggested that arginylation can
occur only on N-terminally exposed Asp, Glu, and Cys [24]
and that such arginylation should result in a decrease in
metabolic stability and increase in protein degradation by the
ubiquitin-dependent N-end rule pathway [22]. Our study
expands this view and demonstrates that arginylation can also
occur on other residues and that in many, apparently the
Figure 4. Selected MS/MS Spectra for the Arginylated Peptides Shown in Table 1
Peptide sequences are shown on top of each spectrum, with the added Arg boxed in red. Observed b and y ions are shown in red and blue, respectively
on the MS/MS spectra and in the corresponding tables for each spectra. Generic names of the proteins are shown underneath the corresponding
spectra. The spectra show peptides arginylated on N-terminal alanine (Ala), Leu, Gly, and phenylalanine (Phe) residues, all of which were previously
believed to be unable to serve as an Arg acceptor site. Precursor mass accuracies for the shown spectra are 2.1 ppm (Ala), 3.8 ppm (Leu), 8.0 ppm (Gly),
and 5.6 ppm (Phe). See Table 1 for accession numbers and arginylated positions and Dataset S1 for larger scale images of the MS/MS spectra for all
identified residues.
doi:10.1371/journal.pbio.0050258.g004
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Posttranslational Protein Arginylationmajority of cases, it does not result in protein degradation. It
has been previously shown that beta actin regulation by
arginylation involves structural rearrangements of actin
polymers without an effect on its metabolic stability [8].
The current study is in agreement with this ﬁnding and
suggests that N-terminal arginylation regulates structural
properties of a number of other proteins. It should be noted
that since our analysis by its nature was biased to proteins
abundant (and therefore not degraded) in the wild-type
extracts, those proteins that are metabolically destabilized
upon arginylation are not a part of the current study, and the
conclusions presented here do not take such proteins into
account. Therefore, we must acknowledge the possibility that
another subset of arginylated proteins exists in vivo that
follow different rules than the proteins described here. We
expect, however, that some similarities should exist that
would be common to the arginylation reaction and its
function in vivo.
Since most of the proteins in our analysis were found to be
arginylated on the residues internal to the initiator Met, it is
clear that for such proteins arginylation involves preceding
cleavage by proteases or multiple aminopeptidases, or occurs
on the side chains, where chemically possible. It has been
previously shown that Glu residue can be arginylated on the
side chain [2], which suggests that Asp—which has a similar
side chain—can also be arginylated by the same mechanism.
Stretching this analogy further, it is also possible to suggest
that Asn and Gln can be arginylated with or without
Figure 5. 8-kDa Dynein Light Chain Is Arginylated on N-Terminal Met
That Is Exposed on the Molecule Surface
Crystal structure (left) and primary amino acid sequence (right) of 8-kDa
dynein light chain with the arginylated position marked in yellow on the
polypeptide chain and denoted with red letter R. Arginylation results in
modification of the protein surface, expected to affect molecular
interactions and possibly association with the dynein polypeptide
complex.
doi:10.1371/journal.pbio.0050258.g005
Figure 6. Structural Models of Proteins Regulated by Arginylation
Three-dimensional structures of proteins downloaded from the National Center for Biotechnology Information structure database at http://www.ncbi.
nlm.nih.gov/ (PDB identifiers 1HLU for beta actin, 1TUB for tubulin, 1DXT for hemoglobin, and 1ZNQ for GADPH) with arginylated positions highlighted
in yellow within the polypeptide chains and marked with red letters R. Alpha and beta for tubulin indicate the corresponding polypeptide chains. See
Text S1 for explanation of the functional significance of the arginylated sites in each shown protein.
doi:10.1371/journal.pbio.0050258.g006
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Posttranslational Protein Arginylationdeamidation, that lysine (Lys) can accept Arg onto its side
chain amino group, and that serine, threonine, and Cys can
be arginylated on the side chains after oxidation.
The ﬁnding that a large subset of arginylation sites are
either exposed on the molecule surface or located at a clear
boundary between two protein domains suggests an interest-
ing possibility of protein regulation by arginylation (Figure
7). While it is possible that in some cases arginylation occurs
after degradatory proteolysis of damaged proteins (left
branch of the pathway in Figure 7), it is notable that
apparently only a relatively small fraction of the peptides in
vivo are arginylated, suggesting that the speciﬁcity for the
arginylated sites must be fairly high. In fact, as shown here,
this speciﬁcity may involve structural motifs on the protein
surface and amino acids within the polypeptide located on
the N-terminal side of the arginylated residues (Figure S1),
suggesting that the recognition of the arginylated sites occurs
prior to proteolytic cleavage. It is also notable that, based on
the known three-dimensional structures, the majority of the
arginylated sites are accessible for arginylation on the surface
of the intact protein molecules or subunits (as seen in the
cases shown in Figures 5 and 6 and observed for all other
analyzed structures) or after an interdomain cleavage that
would be likely to produce functional protein fragments
(middle branch of the pathway in Figure 7). Based on the facts
that recognition of the arginylated sites appears to precede
proteolytic cleavage and that such sites in many cases are
found in a limited number of surface sites, we propose a new
mechanism for protein regulation that would involve limited
proteolysis by ‘‘snipping’’ the polypeptide chain without
breaking down the tertiary structure of the molecule, and the
subsequent arginylation (right branch of the pathway in
Figure 7). It seems possible that such proteolysis could
h a p p e ni nv i v ow i t h o u tb r e a k i n gd o w nt h eq u a t e r n a r y
structure of the protein molecule, held together by non-
covalent interactions or covalent crosslinking of the amino
acid side chains [25]. In fact, internal arginylation sites are
found in proteins (shown in Tables 1 and S3) that are excised
from the SDS gel spots of their expected molecular weight,
suggesting that covalent crosslinking in vivo is holding them
together after internal cleavage and arginylation. This
possibility constitutes an exciting direction of further study.
Additional levels of regulation of protein arginylation
could be imagined. First, it is possible that for those
substrates that are arginylated after denaturation and
cleavage, addition of N-terminal Arg causes their degrada-
Figure 7. Protein Regulation by Arginylation
Top: schematic representation of a protein containing two subunits (I, magenta and brown, and II, blue), whose subunit I is divided into two structurally
and functionally distinct subdomains (A and B) within the same polypeptide chain. Middle: proteolytic products of this protein produced by
degradation (left), interdomain cleavage (middle), or hypothetical intrachain proteolysis that occurs without the loss of the tertiary structure (right).
Bottom: arginylation of the N-termini exposed during these proteolytic events could either produce denatured arginylated peptides (left), modulate the
surface properties of active protein fragments (middle), or modulate the surface properties of the intact molecule (right). The last case also includes side
chain arginylation, where Arg could be added onto the side chain of Asp or Glu (or possibly other residues) without proteolytic cleavage. Letters R in
different colors indicate Arg residues added onto the damaged protein products (white), functional sites on the surface of proteins or domains (red),o r
side chains exposed on the protein surface (green).
doi:10.1371/journal.pbio.0050258.g007
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Posttranslational Protein Arginylationtion, as has been suggested by the N-end rule studies. Such a
mechanism would involve massive proteolysis in wild-type
cells and accumulation of the corresponding targets in the
Ate1
 / cells, which could account for a subset of arginylation-
related changes observed in our analysis. Based on our data
and the work of other groups, there is currently no solid
evidence that this mechanism regulates a large number of
arginylated proteins, but we cannot exclude the possibility
that some of the arginylated targets are indeed destabilized,
in a speciﬁc or nonspeciﬁc way.
A second possibility of arginylation regulation concerns
competition with other posttranslational modiﬁcations for
the free N-termini. It has been previously shown that a
majority of eukaryotic proteins are acetylated in vivo [26,27].
It seems likely that acetylation and arginylation reactions,
which can occur on the same alpha amino groups of the same
residues, are in competition in vivo and that the fractions of
acetylated versus arginylated forms of each protein are
regulated by this competition. Such a situation most likely
happens in the case of beta actin, which is found in vivo in
both acetylated and arginylated forms [8].
Finally, regulation of arginylation is likely to involve de-
arginylation enzymes that should cleave off N-terminal Arg to
regulate the fraction of arginylated protein versus its non-
arginylated form in important metabolic pathways. A likely
candidate for such a role is aminopeptidase B [28], which
selectively removes Lys and Arg from the N-terminus of
certain regulatory peptides and could feasibly perform a
similar function for other arginylated proteins. It is also
possible that other de-arginylation enzymes with broad or
narrow speciﬁcity exist in vivo and may be involved in
regulation of arginylation.
The results of this study suggest that arginylation is a global
form of regulation of activity, abundance, and structure of
multiple proteins in vivo, reminiscent of protein phosphor-
ylation, and that it involves its own machinery of arginyl-
transferases, cofactors, and de-arginylation enzymes that is
responsible for controlling vital physiological processes. Like
protein phosphorylation, arginylation is likely to regulate
different proteins in different ways that would modulate their
assembly and structure (as seen in the case of beta actin),
metabolic stability (as seen with regulators of G-protein
signaling RGS4, RGS5, and RGS16), or other properties that
facilitate their intracellular functions and roles in cardiovas-
cular development, angiogenesis, and other important bio-
logical processes. Studies of this modiﬁcation constitute an
exciting emerging ﬁeld.
Materials and Methods
Protein fractionation and analysis. Comparative 2D gel electro-
phoresis shown in Figure 1 was performed using frozen cell pellets
prepared from cell monolayers of wild-type cells, wild-type cells
treated with 2 mM proteasome inhibitor MG-132 (Sigma-Aldrich,
http://www.sigmaaldrich.com/), and Ate1
 /  cells, collected by scraping
and centrifugation for 59 at 1,000 rpm. Samples were lysed in 2D lysis
buffer containing 30 mM Tris-HCl (pH 8.8), 8 M urea, and 4%
CHAPS, and sonicated for 5 s using VirSonic 100 (VirTis, http://www.
virtis.com/) at power level 4, followed by vigorous shaking at room
temperature for 30 min and clariﬁcation by high-speed centrifuga-
tion for 30 min. Supernatants were transferred to fresh eppendorf
tubes, and protein concentration was adjusted to 5 mg/ml for each
sample with lysis buffer. For Cy dye labeling, Cy2, Cy3, and Cy5
(Amersham, http://www.amersham.com/) were diluted 1:5 with di-
methyl formamide prior to use, mixed with the samples, and
incubated on ice for 30 min, followed by addition of 0.7 llo f1 0
mM Lys and additional incubation on ice in the dark for 15 min. For
the 2D gel analysis, equal amounts of samples were mixed with the
sample buffer and fractionated as described in [29]. Gels were
visualized in three ﬂuorescence channels, scanned using Typhoon
Trio scanner (Amersham), and analyzed using ImageQuant software
for imaging and DeCyder software for quantiﬁcation (Amersham).
Sample preparation from frozen cell pellets, 2D gel fractionation, and
analysis of the data shown in Figure 1 were performed with the help
of Applied Biomics (http://www.appliedbiomics.com/). For the bar
chart in Figure 1B and Table S4, spots up- or down-regulated by 1.5-
fold or more were considered.
Gels for protein identiﬁcation shown in Tables S1–S3 were run and
analyzed by Kendrick Laboratories (http://www.kendricklabs.com/) as
described below. For manual computerized comparisons of protein
abundance in the spots used for spot excision and protein
identiﬁcation shown in Tables S1–S3, integrated density (volume)
for each spot on the high-resolution scanned images of gels or
autoradiographs was expressed as a percentage of total density of all
spots measured, and the difference in abundance was deﬁned by the
fold-change of the spot percentage value compared to the spot’s
matched counterpart in the comparison gel. Spots with altered
volume percentage were deﬁned by the ratio of the percentages in
the two gels and deﬁned as positive (for up-regulation) or negative
(for down-regulation). Gels were analyzed in duplicates and Student’s
t-test values were generated by the software for the n-fold change
averaged from two gels. For protein identiﬁcation, spots up- or down-
regulated 2-fold or more were considered; the most abundant of
these spots were subjected to MS identiﬁcation, with the results
shown in Tables S1–S3.
Posttranslational incorporation of Arg into cultured cells. This
analysis was performed as described in [9] with some modiﬁcations.
Cell monolayers were placed into custom-prepared serum-free
DMEM without Arg supplemented with 10 lg/ml cycloheximide and
incubated for 3 h to suppress protein synthesis and induce Arg
starvation. Medium was then supplemented with 5 lCi of
14C-Arg
(Moravek Biochemicals, http://www.moravek.com/) and incubated for
additional 3 h at 37 8C under normal growth conditions. After
incubation, medium was removed and cells were dissolved in SDS
sample buffer for 2D electrophoresis shown in Figure 2. 2D gels and
autoradiography were performed by Kendrick Laboratories. For
identiﬁcation of proteins in the spots that showed increased Arg
incorporation above the Ate1
 /  background, duplicate gels of
untreated cell extracts were run, and spots were excised from the
Coomassie-stained gels superimposed on the autoradiographs shown
in Figure 2. Protein identiﬁcation for this experiment was performed
by Midwest Bio Services (http://www.midwestbioservices.com/).
Antibody generation and immunoafﬁnity chromatography. Initial
synthesis of the peptides shown in Figure 3, immunizations, and
collection of antisera were performed by Sigma Genosys (http://www.
sigmaaldrich.com/Brands/Sigma_Genosys.html). Crude antiserum
was afﬁnity puriﬁed on the peptides used for immunization and
then immunodepleted as shown in Figure 3 using agarose beads with
covalently linked peptides, and puriﬁed antibodies were covalently
coupled to Aminolink agarose (Pierce). Whole lysates of mouse
organs (brain, liver, kidney, spleen, heart, and lungs), embryonic day
12 embryos, and cultured ﬁbroblasts, clariﬁed by high-speed
centrifugation, were preabsorbed on the column with coupled
preimmune serum. The resulting extracts were bound to the antibody
columns, and arginylated proteins were eluted with Gly (pH 2.7) or
3.5 M MgCl2. Protein mixtures were precipitated with trichloroacetic
acid, resuspended in physiological buffer, and digested with a cocktail
of proteases including various combinations of trypsin, subtilisin,
elastase, and endopeptidase Lys-C. Proteins in the resulting digests
were identiﬁed by MS as described below.
Peptide synthesis. Standard peptides for the validation of the MS
data and performing immunoafﬁnity puriﬁcations and antibody
characterization during the later stages of the project were
synthesized in collaboration with the Proteomics Resource Center,
Rockefeller University (http://pdtc.rockefeller.edu/). All peptides were
created using a SYMPHONY multiple peptide synthesizer (Protein
Technologies, http://www.pti-instruments.com/) on Wang resin (Bach-
em, http://www.bachem.com/) using Fmoc protected amino acids
(AnaSpec, http://www.anaspec.com/) [30]. Coupling reactions were
conducted using 0.3 M HBTU or HATU/HOBT and 0.4 M NMM or 0.6
M DIPEA in N-methylpyrrolidinone as the primary solvent [31].
Simultaneous resin cleavage and side chain deprotection were
achieved by treatment with concentrated, sequencing-grade tri-
ﬂuoroacetic acid with triisopropylsilane, water, and ethanedithiol in
a ratio of 95:2:2:1 for a 3- to 6-h time frame. Rotary evaporation
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acetic acid from the resin-bound peptides. Peptides were then
released in 8 M acetic acid and ﬁltered from resin, the acidic mixture
was evaporated, and the peptides were redissolved in HPLC-grade
water for lyophilization. All crude lyophilized products were
subsequently analyzed by reversed-phase (RP) HPLC (Waters, http://
www.waters.com/) using a Merck (http://www.merck.com/) Chromolith
Performance C18 column. Individual peptide integrity was veriﬁed by
matrix-assisted laser desorption ionization (MALDI) MS using a
PerSeptive/Applied Biosystems (http://www.appliedbiosystems.com/)
Voyager delayed extraction spectrometer system [32].
Single RP and multi-dimentional (MudPIT) liquid chromatography,
MS, and database searching. Protein digestion was performed in both
gel and solution forms. The cut gel pieces were washed by Milli-Q
water (Millipore, http://www.millipore.com/) and a 1:1 mixture of
water/acetonitrile, and destained with pure acetonitrile and 100 mM
ammonium bicarbonate (Sigma-Aldrich). Protein pellet was dissolved
in Invitrosol LC/MS protein solubilizer following the manufacturer’s
protocol (Invitrogen, http://www.invitrogen.com/). The solution was
reduced and alkylated with 10 mM Tris(2-carboxyethyl)phos-
phine hydrochloride (Roche Applied Science, http://www.
roche-applied-science.com/) and 55 mM iodoacetamide (Sigma-
Aldrich) in 100 mM ammonium bicarbonate. Digestion was
performed in the presence of 50 mM ammonium bicarbonate and 5
mM calcium chloride (Sigma-Aldrich) using sequencing-grade soluble
trypsin (Promega, http://www.promega.com/) or endopeptidase Lys-C
(Roche Applied Science, http://www.roche-applied-science.com/). The
resulting peptides were extracted by 5% formic acid and redissolved
into buffer A (5% acetonitrile with 0.1% formic acid) prior to the
liquid chromatography MS/MS analysis. Peptide mixtures were
pressure-loaded onto a RP or strong cation exchange/RP MudPIT
column and eluted with a linear gradient of acetonitrile or pulses of
ammonium acetate salt (5%–100%). Synthetic peptides were dis-
solved in water and supplemented with 1% formic acid to the ﬁnal
concentration of 100 fmol/ll and analyzed under the same liquid
chromatography MS/MS conditions as those used for the real samples.
Data-dependent MS/MS analysis was performed in a LTQ-Orbitrap
mass spectrometer (Thermo Fisher Scientiﬁc, http://www.thermo.
com/). Full MS spectra were acquired by the precursor ion scan using
the Orbitrap analyzer with resolution set at 60,000, followed by nine
MS/MS events in the linear ion trap (LTQ), sequentially generated on
the ﬁrst-, second-, and third-most intense ions selected from the full
MS spectrum. MS scan functions and HPLC solvent gradients were
controlled by the Xcalibur data system (Thermo Fisher Scientiﬁc).
Tandem mass spectra were searched against European Bioinfor-
matics Institute International Protein Index mouse protein database
(version 3.06, release date 10 May 2005; http://www.ebi.ac.uk/IPI/) that
was concatenated with reversed sequences to estimate false positive
rate using the ProLuCID [33] protein database search algorithm with
peptide mass tolerance of 63 amu, fragment ion mass tolerance of
60.4 amu, and a static modiﬁcation of 57.0215 on Cys due to
carboxyamidomethylation. This program has been modiﬁed to add
the capability of performing N- and C-terminal differential mod-
iﬁcation searches. In order to identify N-terminal arginylated
peptides, differential N-terminal modiﬁcation of 156.1011 (the
monoisotopic mass of an Arg residue) searches were performed with
no enzymatic cleavage conditions imposed on the database search.
For each spectrum, ProLuCID searches the protein database twice.
On the ﬁrst round it assumes no modiﬁcation (mass shift) on any
candidate peptides, and on the second round it assumes that each
peptide has a mass shift of 156.1011 at the N-terminus of the
peptides. It is worth noting that users do not need to specify what
residues can have the modiﬁcation. An N-terminal modiﬁcation is
considered for each peptide within the given mass tolerance,
regardless of what residue is located at the N-terminus. The program
computes a binomial probability score for each candidate peptide
based on the number of theoretical peaks that match experimental
peaks and the complexity of the spectra. Like SEQUEST [20,21], for
each spectrum, ProLuCID selects 500 peptides that are least likely to
be random hits based on the binomial probability score and applies
an improved cross-correlation algorithm to compute a cross-
correlation score (XCorr) and a normalized difference in cross-
correlation score (DeltaCN) for each of these 500 peptides. The ﬁnal
results are sorted by XCorr.
ProLuCID search results were then ﬁltered with DTASelect 2.0 [34]
using XCorr and DeltaCN at a false positive rate of 0.1% (–fp 0.001)
estimated by number of reverse hits. Only half or fully tryptic (–y 1)
peptides with N-terminal arginylation (–m 0) and a DeltaMass   5
ppm (–DM 5) were accepted; the minimum number of peptides to
identify a protein was set to 1(–p 1). The ﬁnal proteins with
arginylation modiﬁcations that passed these ﬁltering criteria and
manual validation are listed in Table 1.
Supporting Information
Dataset S1. MS/MS Spectra of the N-Terminally Arginylated Peptides
for Proteins Shown in Table 1
Peptide sequence, accession number, and protein name are listed on
top of each spectrum. N-terminally arginylated Ile, Gln, and Arg were
not found. One protein was found to be arginylated on initiator Met
(Figure 19), and two more cases of arginylation on internal Met have
been found (Figures 5 and 20).
Found at doi:10.1371/journal.pbio.0050258.sd001 (485 KB PDF).
Dataset S2. MS/MS Spectra for the Standard Peptides Used to
Differentiate N-Terminal Arg (Figure 1) and Val–Gly (Figure 2)
Residues in the Peptides
While precursor masses of the two peptides are similar, the
arginylated peptide shows prominent peaks for b ions, while the
spectrum for the peptide with N-terminal Val–Gly is abundant in y
ions only.
Found at doi:10.1371/journal.pbio.0050258.sd002 (34 KB PDF).
Figure S1. Frequencies of Occurrence of Different Amino Acids in
the Arginylated Position and 20 Flanking Positions on Each Side of
the Arginylated Residue Calculated with the Online WebLogo Tool
Letter size corresponds to the frequency of the residue occurrence in
each position adjusted to the total frequency of its occurrence in vivo.
Found at doi:10.1371/journal.pbio.0050258.sg001 (23 KB PDF).
Table S1. Proteins Up- or Down-Regulated in Response to Ate1
Knockout
Found at doi:10.1371/journal.pbio.0050258.st001 (128 KB DOC).
Table S2. Proteins Up-Regulated in Response to Proteasome
Inhibition
Found at doi:10.1371/journal.pbio.0050258.st002 (46 KB DOC).
Table S3. Proteins Identiﬁed in the Spots That Posttranslationally
Incorporate Arg in Cultured Fibroblasts
Found at doi:10.1371/journal.pbio.0050258.st003 (162 KB DOC).
Table S4. 2D Gel Protein Spot Comparison between Wild-Type Cells,
Wild-Type Cells Treated with Proteasome Inhibitor, and Ate1
 /  Cells
WT, wild-type cells; WTPI, wild-type cells treated with proteasome
inhibitor.
Found at doi:10.1371/journal.pbio.0050258.st004 (33 KB DOC).
Text S1. Detailed Discussion of Figure 6: Possible Ways of Regulation
of Actin, Tubulin, Hemoglobin, and GAPDH by Arginylation
Found at doi:10.1371/journal.pbio.0050258.sd003 (56 KB DOC).
Accession Numbers
The Mouse Genome Informatics (http://www.informatics.jax.org/) IDs
for proteins discussed in this paper are actin (87904), aminopeptidase
B (2384902), ARP3 (2661120), beta actin (87904), talin (1099832), and
vimentin (98932).
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